STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCRX
  4. [Form 4] Pacira BioSciences, Inc. Insider Trading Activity

Pacira BioSciences (PCRX) director Laura Brege receives stock and option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pacira BioSciences director Laura Brege reported equity awards consisting of restricted stock units and stock options. She received 6,405 shares of common stock as a grant, bringing her directly held common shares to 30,120. She was also granted options for 10,891 shares at an exercise price of $23.42 per share.

The 6,405 restricted stock units vest on June 10, 2027, if she remains in continuous service with Pacira through that date. The stock options also vest on June 10, 2027 under the same service condition and will expire on June 10, 2036 if not exercised.

Positive

  • None.

Negative

  • None.
Insider Brege Laura
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 10,891 $0.00 --
Grant/Award Common Stock 6,405 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 10,891 shares (Direct, null); Common Stock — 30,120 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Restricted stock units granted 6,405 shares Award of common stock that vests on June 10, 2027
Common shares held after grant 30,120 shares Direct holdings following the June 10, 2026 award
Stock options granted 10,891 options Right to buy common stock, granted June 10, 2026
Option exercise price $23.42 per share Conversion or exercise price for 10,891 options
RSU vesting date June 10, 2027 Vesting requires continuous service through this date
Option vesting date June 10, 2027 Options become exercisable if service condition is met
Option expiration date June 10, 2036 Options lapse if not exercised by this date
restricted stock units financial
"Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
continuous service financial
"provided that the reporting person remains in continuous service with the issuer through the vesting date"
vesting date financial
"remains in continuous service with the issuer through the vesting date"
exercise price financial
"conversion_or_exercise_price: "23.4200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brege Laura
(Last)(First)(Middle)
C/O PACIRA BIOSCIENCES, INC.
2000 SIERRA POINT PARKWAY, SUITE 900
(Street)
BRISBANE CALIFORNIA 94005
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A6,405(1)A$030,120D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$23.4206/10/2026A10,89106/10/2027(2)06/10/2036Common Stock10,891$010,891D
Explanation of Responses:
1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
2. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Remarks:
/s/ Kristen Williams, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Pacira BioSciences (PCRX) director Laura Brege report?

Laura Brege reported awards of restricted stock units and stock options. She received 6,405 common shares as a grant and options covering 10,891 shares, all tied to continued service through June 10, 2027.

How many Pacira BioSciences (PCRX) shares does Laura Brege hold after the Form 4 awards?

After the reported grant, Laura Brege directly holds 30,120 shares of Pacira common stock. This reflects the addition of 6,405 awarded shares to her existing position, as shown in the Form 4 transaction details.

What are the key terms of Laura Brege’s stock option grant at Pacira BioSciences (PCRX)?

The stock option grant covers 10,891 shares of Pacira common stock at a $23.42 exercise price. The option vests on June 10, 2027 if she remains in continuous service and expires on June 10, 2036.

When do Laura Brege’s restricted stock units in Pacira BioSciences (PCRX) vest?

The 6,405 restricted stock units vest on June 10, 2027. Vesting requires that Laura Brege remain in continuous service with Pacira BioSciences through that vesting date, according to the Form 4 footnote disclosure.

Are Laura Brege’s Pacira BioSciences (PCRX) equity awards open-market purchases or compensation grants?

The Form 4 classifies both transactions as grants or awards, not open-market purchases. The restricted stock units and stock options are compensation-related acquisitions, contingent on her continued service with Pacira through June 10, 2027.